Skip to content

OUTCOME AND SAFETY OF RECANALIZATION TREATMENTS IN ISCHEMIC STROKE DUE TO ACUTE BASILAR ARTERY OCCLUSION

RECANALISATION THERAPY IN ISCHEMIC STROKE DUE TO BASILAR ARTERY OCCLUSION IN PEOPLE 115 HOSPITAL, VIETNAM

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05402878
Enrollment
150
Registered
2022-06-02
Start date
2021-08-01
Completion date
2023-12-31
Last updated
2022-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basilar Artery Occlusion

Keywords

BASILAR ARTERY OCCLUSION, RECANALISATION THERAPY

Brief summary

Rationale: Recently, two prospective multicenter RCT reported a potential beneficial effect of endovascular thrombectomy (EVT) in patients with an acute symptomatic basilar artery occlusion (BAO). However, the high rate of crossover in BEST study and the long-term of recruitment in BASICS study influenced the validity of the results. Objective: To assess the outcomes and prognostic factors of recanalization therapy in patients with BAO, caused by a CTA/MRA/DSA confirmed occlusion of the basilar artery. Study design: This is a prospective observational study. Study population: Patients with acute ischemic stroke and a confirmed basilar artery occlusion by CTA/MRA/DSA. Main study parameters/outcomes: Favorable outcome at day 90 defined as a modified Rankin Score (mRS - functional scale) of 0-3. The estimate will be adjusted for the known prognostic variables age, time from onset to treatment, stroke severity (NIHSS), PC ASPECT and collateral flow and adjusted and unadjusted estimates with corresponding 95% confidence intervals will be reported.

Detailed description

Acute basilar artery thrombosis is associated with a poor prognosis. Prevalence of basilar artery occlusion are not known in Vietnam.Various treatments were tried in groups of patients with acute ischemic stroke due to basilar artery occlusion, but evidence based was not cleared previous studies. Therefore, we conduct this study to evaluate the efficacy and safety of recanalization therapies, which included intravenous thrombosis alone, endovascular alone, or bridging IVT and endovascular, in basilar artery occlusion stroke patients.

Interventions

None listed

Sponsors

115 People's Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptoms and signs compatible with ischemia in the basilar artery territory. * Basilar artery occlusion (BAO) confirmed by CTA or MRA or DSA. * Age 18 years or older * Patients were treated with one of these among therapies IVT alone, bridging IVT and thrombectomy or thrombectomy alone..

Exclusion criteria

* Patients did not agree to enroll. Imaging

Design outcomes

Primary

MeasureTime frameDescription
favourable outcome90 (± 14 days) after procedurea modified Rankin Score of 0-3

Secondary

MeasureTime frameDescription
good outcome90 (± 14 days) after procedurea modified Rankin Score of 0-2
mortality90 (± 14 days) after procedureNumber of subjects who died at 90-day follow-up/total number of subjects who participated in 90-day follow-up) x100%.
Any intracerebral hemorrhagewithin 72 hours after procedureintracerebral hemorrhage was defined according ECASS definition.
Symptomatic intracerebral hemorrhage (sICH)within 72 hours after procedureSICH means any hemorrhage with neurological deterioration, as indicated by an NIHSS score that was higher by ≥4 points than the value at baseline or the lowest value in the first 72 hours or any hemorrhage leading to death.
Procedural related complicationsPerioperative periodarterial perforation, arterial dissection, embolization in a previously uninvolved vascular territory and so on
Dichotomized mRS score90 (± 14 days) after proceduremRS (0-2 versus 3-6 and 0-4 versus 5-6 )

Countries

Vietnam

Contacts

Primary ContactBich Huong Nguyen
bichhuong.medic@gmail.com+84989689525
Backup ContactHuy Thang Nguyen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026